Cochran Center Clinical Trials
The Cochran Brain Tumor Center is the coordination point for the physicians who specialize in clinical trials. The goal of the center is to shepherd basic research discoveries through patient trials and the government approval process. Researchers at Cedars-Sinai are racing to develop experimental treatments, and even vaccines, for fast-growing malignant tumors.
As a research facility, we often invite our patients to participate in clinical trials of new drugs and other therapies. The following links describe some of the cutting-edge research studies and clinical trials we are currently directing or have completed. For more information about basic science research used to help develop new clinical treatments, visit our Research section.
Newly Diagnosed Glioblastoma Multiforme
- A Phase II Study Of Bevacizumab And Erlotinib After Radiation Therapy And Temozolomide In Patients With Newly Diagnosed Glioblastoma Multiforme Without MGMT Promoter Methylation (More Information)
Newly Diagnosed Glioblastoma Multiforme / Recurrent GBM and Brainstem Glioma
- Cilengitide for Subjects with Newly Diagnosed Glioblastoma Multiforme and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination with Standard Treatment (Temozolomide with Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) versus Standard Treatment Alone(More Information)
Recurrent Glioblastoma Multiforme
- A Phase II Study of Azixa (MPC-6827) for the Treatment of Patients with Recurrent Glioblastoma Multiforme (More Information)
Malignant Glioma
- A Phase I Trial of Surgical Resection Followed by Vaccination with Dendritic Cells Pulsed with Tumor Lysate with Imiquimod for Patients with Malignant Glioma (More Information)
Recurrent Malignant Glioma
- A Phase I/II Trial of BIBW2292 With or Without Daily Temozolomide in the Treatment of Patients with Recurrent Malignant Glioma (More Information)
- A Phase I/II Clinical Trial to Evaluate Dose Limiting Toxicity and Efficacy of Intralesional Administration of REOLYSIN for the Treatment of Patients with Histologically Confirmed Recurrent Malignant Gliomas (closed for recruitment)
Meningioma
- A Phase II Study of SOM230C in Patients with Recurrent or Progressive Meningioma who have Previously undergone or are not Candidates for Additional Surgery or Radiation (More Information )
Recurrent High Grade Gliomas and Brain Metastases
- Pilot Study of Phosphodiesterase-V Inhibition to Increase Intratumoral Concentration of Carboplatin in Patients with Recurrent High Grade Gliomas and Brain Metastases (More Information )
For an appointment, a second opinion or more information, please call 1-800-CEDARS-1 (1-800-233-2771) or e-mail us.
